Axsome Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering novel therapies for the management of central nervous sys...
Data could not be retrieved
| Metric Name | Value | Trend | |
|---|---|---|---|
| Dividend Yield | 0.0% | ||
| P/E Ratio | -16.2x | ||
| Revenue | 385.7 M | ||
| Net Income to Company | -287.2 M |
| AXSM | Peers | Sector | |
|---|---|---|---|
Market Cap | 4.664 B | 643.8 M | 59.688 M |
Price % of 52 Week High | 68.7% | 40.2% | 57.5% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | -1.6% | -6.2% | -0.7% |
1 Year Price Total Return | 36.7% | -21.0% | -16.5% |
Beta (5 Year) | 0.88 | 0.91 | 0.64 |
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 50 | 271 | 386 | 72 | 119 |
| Operating Income | (175) | (183) | (252) | (55) | (62) |
| Net Profit | (187) | (239) | (287) | (99) | (75) |
| Diluted EPS | -4.60 | -5.27 | -5.99 | -2.08 | -1.54 |
| EBITDA | (171) | (176) | (244) | (53) | (60) |
| Balance Sheet | |||||
| Cash & ST Invest. | 201 | 386 | 315 | 386 | 315 |
| Current Assets | 246 | 504 | 485 | 504 | 485 |
| Total Assets | 331 | 588 | 568 | 588 | 568 |
| Current Liabilities | 97 | 139 | 230 | 139 | 230 |
| Total Liabilities | 222 | 397 | 511 | 397 | 511 |
| Total Equity | 110 | 191 | 57 | 191 | 57 |
| Total Debt | 95 | 186 | 193 | 186 | 193 |
| Cash Flow Statement | |||||
| Cash Flow Operations | (117) | (145) | (128) | (30) | (26) |
| Cash From Investing | (54) | (0.58) | (0.27) | (0.01) | (0.03) |
| Cash From Financing | 285 | 331 | 58 | 0.00 | 14 |
| Free Cash Flow | (117) | (146) | (129) | (30) | (26) |